AI Article Synopsis
- Ingenol mebutate (IM) is a newly approved topical treatment for actinic keratoses, working through rapid cell death and triggering an immune response to clear abnormal skin cells.
- A case report details a woman with Bowen's disease (BD) on her forefinger that had recurred for 8 years, despite her complex medical history including a stem cell transplant and lung surgery.
- The report highlights the use of dermoscopy to track treatment effects and suggests IM gel as a promising therapeutic option for managing BD.
Article Abstract
Ingenol mebutate (IM) has recently been approved for the topical treatment of actinic keratoses. It appears to have a dual mechanism of action: rapid necrosis after gel application and a subsequent immune-mediated response, which targets any residual dysplastic epidermal cells. We report the successful treatment of a woman, who had been relapsing into Bowen's disease (BD) on her right forefinger for 8 years. During her clinical history, she had received an allogeneic, HLA-identical stem cell transplant for myeloproliferative syndrome with a JAK2V617F mutation and lobectomy of the pulmonary right lower lobe for adenocarcinoma. We used dermoscopy to monitor the therapeutic response of BD. We discuss IM gel as a possible therapeutic option for BD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000447389 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!